Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alastair H Kyle

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Cancer Research|September 3, 2004
Direct assessment of drug penetration into tissue using a novel application of three-dimensional cell cultureAlastair H Kyle, Lynsey A Huxham, Aaron S J Chiam, et al.
International Journal of Radiation Oncology, Biology, Physics|June 2, 2009
Detecting vascular-targeting effects of the hypoxic cytotoxin tirapazamine in tumor xenografts using magnetic resonance imagingLauren J Bains, Jennifer H E Baker, Alastair H Kyle, et al.
Anticancer Research|November 5, 2014
Effect of radiation on cell proliferation and tumor hypoxia in HPV-positive head and neck cancer in vivo modelsBrita Singers Sørensen, Morten Busk, Michael R Horsman, et al.
Scientific Reports|August 1, 2023
DNA-PK inhibition extends the therapeutic effects of Top2 poisoning to non-proliferating cells, increasing activity at a costTaixiang Wang, Alastair H Kyle, Jennifer H E Baker, et al.
Journal of Biomedical Optics|October 11, 2013
Multimodal tissue imaging: using coregistered optical tomography data to estimate tissue autofluorescence intensity change due to scattering and absorption by neoplastic epithelial cellsHamid Pahlevaninezhad, Ivana Cecic, Anthony M D Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenograftsJennifer H E Baker, Kirstin E Lindquist, Lynsey A Huxham, et al.
DNA Repair|May 15, 2024
DNA-PK inhibitor AZD7648 is a more portent radiosensitizer than PARP inhibitor Olaparib in BRCA1/2 deficient tumorsTaixiang Wang, Alastair H Kyle, Jennifer H E Baker, et al.
Molecular Cancer Therapeutics|May 23, 2024
Radiation and Chemo-Sensitizing Effects of DNA-PK Inhibitors Are Proportional in Tumors and Normal TissuesJennifer H E Baker, Alastair H Kyle, Nannan A Liu, et al.
Plos One|November 9, 2013
Targeting the tumour vasculature: exploitation of low oxygenation and sensitivity to NOS inhibition by treatment with a hypoxic cytotoxinJennifer H E Baker, Alastair H Kyle, Kirsten L Bartels, et al.
Cancer Research|November 15, 2012
Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibitionChristopher Daly, Alexandra Eichten, Carla Castanaro, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Cancer Research|September 3, 2004
Direct assessment of drug penetration into tissue using a novel application of three-dimensional cell cultureAlastair H Kyle, Lynsey A Huxham, Aaron S J Chiam, et al.
International Journal of Radiation Oncology, Biology, Physics|June 2, 2009
Detecting vascular-targeting effects of the hypoxic cytotoxin tirapazamine in tumor xenografts using magnetic resonance imagingLauren J Bains, Jennifer H E Baker, Alastair H Kyle, et al.
Anticancer Research|November 5, 2014
Effect of radiation on cell proliferation and tumor hypoxia in HPV-positive head and neck cancer in vivo modelsBrita Singers Sørensen, Morten Busk, Michael R Horsman, et al.
Scientific Reports|August 1, 2023
DNA-PK inhibition extends the therapeutic effects of Top2 poisoning to non-proliferating cells, increasing activity at a costTaixiang Wang, Alastair H Kyle, Jennifer H E Baker, et al.
Journal of Biomedical Optics|October 11, 2013
Multimodal tissue imaging: using coregistered optical tomography data to estimate tissue autofluorescence intensity change due to scattering and absorption by neoplastic epithelial cellsHamid Pahlevaninezhad, Ivana Cecic, Anthony M D Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenograftsJennifer H E Baker, Kirstin E Lindquist, Lynsey A Huxham, et al.
DNA Repair|May 15, 2024
DNA-PK inhibitor AZD7648 is a more portent radiosensitizer than PARP inhibitor Olaparib in BRCA1/2 deficient tumorsTaixiang Wang, Alastair H Kyle, Jennifer H E Baker, et al.
Molecular Cancer Therapeutics|May 23, 2024
Radiation and Chemo-Sensitizing Effects of DNA-PK Inhibitors Are Proportional in Tumors and Normal TissuesJennifer H E Baker, Alastair H Kyle, Nannan A Liu, et al.
Plos One|November 9, 2013
Targeting the tumour vasculature: exploitation of low oxygenation and sensitivity to NOS inhibition by treatment with a hypoxic cytotoxinJennifer H E Baker, Alastair H Kyle, Kirsten L Bartels, et al.
Cancer Research|November 15, 2012
Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibitionChristopher Daly, Alexandra Eichten, Carla Castanaro, et al.
Pageof 3